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Calcium-sensitivityFamilial Hypertrophic Cardiomyopathy (FHC) is frequently caused by mutations in the β-cardiac myosin heavy
chain (β-MyHC). To identify changes in sarcomeric function triggered by such mutations, distinguishing muta-
tion effects from other functional alterations of themyocardium is essential.We previously identiﬁed a direct ef-
fect of mutation R723G (MyHC723) on myosin function in slow Musculus soleus ﬁbers. Here we investigate
contractile features of left ventricular cardiomyocytes of FHC-patients with the same MyHC723-mutation and
compare these to the soleus data.
In mechanically isolated, triton-permeabilized MyHC723-cardiomyocytes, maximum force was signiﬁcantly
lower but calcium-sensitivity was unchanged compared to donor. Conversely, MyHC723-soleus ﬁbers showed
signiﬁcantly higher maximum force and reduced calcium-sensitivity compared to controls. Protein phos-
phorylation, a potential myocardium speciﬁc modifying mechanism, might account for differences compared
to soleus ﬁbers. Analysis revealed reduced phosphorylation of troponin I and T, myosin-binding-protein C, and
myosin-light-chain 2 in MyHC723-myocardium compared to donor. Saturation of protein-kinaseA phospho-sites
led to comparable, i.e., reduced MyHC723-calcium-sensitivity in cardiomyocytes as inM. soleus ﬁbers, while max-
imum force remained reduced. Myoﬁbrillar disarray and lower density of myoﬁbrils, however, largely account
for reduced maximum force in MyHC723-cardiomyocytes.
The changes seenwhenphosphorylation of sarcomeric proteins inmyocardiumof affectedpatients ismatched to
control tissue suggest that the R723G mutation causes reduced Ca++-sensitivity in both cardiomyocytes and
M. soleus ﬁbers. In MyHC723-myocardium, however, hypophosphorylation can compensate for the reduced
calcium-sensitivity, while maximum force generation, lowered by myoﬁbrillar deﬁciency and disarray, remains
impaired, and may only be compensated by hypertrophy.
© 2013 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Familial Hypertrophic Cardiomyopathy (FHC) is the most frequent
genetically transmitted cardiac disease with a prevalence of 1:500 [1].
It is often characterized by asymmetric hypertrophy of left ventricularll Physiology, HannoverMedical
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NC-ND license.(LV)wall and septum and by an increased risk for sudden cardiac death
particularly in young adults [2]. Myocyte disarray and interstitial ﬁbro-
sis are hallmarks of FHC. Nearly all genotyped FHC cases revealedmuta-
tions in sarcomeric proteins. Yet, the underlying functional changes at
the cardiomyocyte level possibly initiating disease development are
still largely unknown.
To investigate mechanisms triggering FHC pathogenesis we focused
on mutations in the β-cardiac myosin heavy chain (β-MyHC) gene
(MYH7). MYH7 mutations are responsible for approximately 30–40%
of all genotyped FHC cases [3]. Theβ-MyHC isoform is expressed in ven-
tricular myocardium and in slow-twitch skeletal muscle ﬁbers [4–6].
We have previously studied functional effects of different β-MyHC-
missense mutations in slow-twitch ﬁbers of Musculus soleus. Data on
functional effects of FHC-related β-MyHC-mutations in human ventric-
ular cardiomyocytes are, however, scarce [7–10].
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myocardium vs. slow twitch skeletal muscle when two severely af-
fected FHC patients carrying β-MyHC-mutation R723G (MyHC723)
[11] underwent heart transplantation and their LV myocardium be-
came available. The LV of both FHC-patients with MyHC723 was func-
tionally equivalent to that of end-stage heart failure (HF). We had
previously characterized the MyHC723 effects in M. soleus ﬁbers
from one of these patients [12,13]. Analysis showed that the direct
functional effect of the mutation, which is located in the converter
domain of the myosin head, is to cause reduced calcium-sensitivity
in soleus ﬁbers and a 20% increase in maximum force generation.
The force increase was found to be due to increased force generation
by the individual mutated myosin heads because of increased molec-
ular stiffness. There was no evidence of adaptational processes in the
M. soleus ﬁbers with MyHC723.
Having now both soleus and myocardial tissue, in one case even
from the same individual, we asked whether the effects of mutation
MyHC723 on contractile function are the same in cardiomyocytes and
slow ﬁbers of M. soleus. In addition, this required us to clarify also
whether cardiomyocyte function is affected by other alterations of
myocardial contractility such as changes in protein phosphorylation.
From studies on human cardiac tissue it is known that end-stage HF is
characterized by desensitization of the β-adrenergic pathway resulting
in e.g., dephosphorylation of cardiac troponin I (cTnI) [14], Myosin-
Binding-Protein C (cMyBP-C) [15], and titin [16]. To assess morpholog-
ical features which might affect function such as myocyte and
myoﬁbrillar organization, we also performed structural studies by
light- and electron microscopy of ventricular tissue from patients and
donors.
2. Methods and materials
An expanded Materials and methods section is included in the on-
line supplementary data.
2.1. Patients and cardiac biopsies
Myocardial tissue was obtained upon cardiac transplant from the LV
of a male patient (H27), age 55 years, from family 26, II-5, and a female
patient (H29), age 53 years, from family 11, III-8, see Enjuto et al. [11].
Genotyping and clinical details of the patients were published previous-
ly [11,17], information about their medication and clinical status at
the time of heart transplant are given in Supplementary Table 1. M.
soleus tissue was obtained from patient H27 one year before HT
[12]. Both patients are heterozygous for β-MyHC-mutation R723G
and had initially developed the classical clinical phenotype of FHC
with diastolic dysfunction, hypertrophy of the LV wall and
interventricular septum, ST–T wave abnormalities, pathological
Q-wave (patient H29) and heart blocks, similar to other related and
unrelated carriers with mutation R723G. The patient's hypertrophic
cardiomyopathy eventually progressed into LV dilatation and
end-stage systolic heart failure (NYHA III–IV) [11,17]. Development
of heart failure is found in a subgroup of FHC patients [2].
Control tissue was from non-transplanted donor hearts (n=5,
23–52 years of age, mean age 39±6 years; 2 female, 3 male) for
which no suitable recipient was found. Our previous studies showed
no age-dependent differences in any of the parameters of sarcomere
function in control cardiomyocytes [18]. For preservation of the tissue
see [12] and data supplement. Approval of the local ethics commit-
tees and written informed consent for use of the tissue were obtained.
2.2. Force and rate constant of force redevelopment (ktr) measurements
in single cardiomyocytes
Force measurements were performed on single, mechanically
isolated cardiomyocytes as described previously [19]. Permeabilizedsingle myocytes were attached to a motor and force transducer with
silicone adhesive. Force–pCa-relations were obtained from force mea-
surements in solutions of different calcium-concentrations. Maxi-
mum active force (Fmax) was obtained by subtracting passive force
from the total force, i.e. Fmax=Ftotal−Fpassive. ktr, the rate constant
of force redevelopment, was measured during isometric contraction
after a short period of unloaded isotonic shortening of the myocytes
[20]. Force measurements were repeated after incubation of cells
with protein kinase A (PKA) or with protein phosphatase-1 (PP-1),
i.e. after adjusting phosphorylation levels between donor and MyHC723
cardiomyocytes.
2.3. β-Myosin-mRNA quantiﬁcation
Relative abundance of mutated vs. wild-type MYH7-mRNA was
determined by a speciﬁc restriction digest approach and by real-time
PCR (RT-qPCR) as described recently [21]. A detailed description is
implemented in the Supplementary material.
2.4. Myoﬁlament protein phosphorylation
Protein phosphorylation was determined as previously described
[22]. Tissue samples were separated on gradient gels (Criterion Tris–
HCl 4–15% gel, BioRad) and phosphorylated proteins were detected
with Pro-Q Diamond staining (Life Technologies, Darmstadt, Germany).
For protein content, gels were stained with SYPRO-Ruby (Life Tech-
nologies, Darmstadt, Germany). Phosphorylation of myoﬁlament
proteins was determined relative to protein expression of cMyBP-C.
For two-dimensional gel electrophoresis samples were loaded on
immobiline strips with a pH gradient of 4.5 to 5.5 (GE Healthcare,
Uppsala, Sweden). In the second dimension, proteins were separated
by SDS-PAGE and stainedwith Coomassie blue.Myosin heavy chain iso-
form analysis was performed on SDS polyacrylamide gels with 5% poly-
acrylamide in stacking gel and 8.8% polyacrylamide and 5% glycerol in
separation gel. Proteins were separated for 30 h at 4 °C.
2.5. Light- and electron microscopy
Tissue was prepared for histological and electron microscopical
(EM) analysis as described [23]. For histology, tissue sections were
Elastica van Gieson-stained. Myoﬁbrillar density was analyzed on
EM images by calculating the sum of myoﬁbrillar areas over the total
cell area in ﬁve representative myocytes per sample (total of at least
35 cells).
2.6. Data analysis
Force–pCa relationswere ﬁt to amodiﬁedHill-equation [19]. Results
are given as mean±SEM. Differences between donor and MyHC723-
myocyte groups were examined by two-sample unpaired Student
t-test with p valuesb0.05 considered as statistically signiﬁcant. Effects
of PKA in donor and MyHC723 samples, respectively, were tested by
one-way ANOVA and Tukey's mean value comparison. A probability
valueb0.05 was considered signiﬁcant for ANOVA.
3. Results
3.1. Unexpected low force generation and unchanged calcium-sensitivity
in MyHC723 cardiomyocytes
For functional characterization of FHC mutation R723G in cardiac
tissue, we investigated isometric force and calcium-sensitivity of isolat-
ed, skinned cardiomyocytes (Figs. 1A and B). Cardiomyocytes were iso-
lated from3 LVwall regions and the septumof patient H27, fromone LV
region of patient H29, and 5 donors, respectively. Maximum force
(Fmax) was signiﬁcantly reduced in MyHC723 myocytes (23.8±
15T. Kraft et al. / Journal of Molecular and Cellular Cardiology 57 (2013) 13–221.7 kN/m2, 67 cells) compared with donor (34.7±3.8 kN/m2, 19
cells) (Fig. 1C). Calcium-sensitivity of MyHC723 cardiomyocytes
(pCa50=5.56±0.01) was not different from donor cells (pCa50=
5.56±0.01) (Fig. 1D). Both results are strikingly different from data
observed previously in slowM. soleus ﬁbers of two FHC patients express-
ing MyHC723, one of whom was patient H27. In slow soleus ﬁbers with
MyHC723 Fmax was increased by 22.8% and the calcium-sensitivity
was reduced (ΔpCa50 of control vs.MyHC723was 0.14) [12,13]. Compar-
ison of absolute forces at different calcium-concentrations (pCa) in
cardiomyocytes from the MyHC723 patients (H27 and H29) vs. donor
(Fig. 1E), and of M. soleus ﬁbers of patient H27 vs. healthy controls
(Fig. 1F) reveals the discrepancies in maximum force and calcium de-
pendence of force in the two tissues. The variance of the force–pCa
curves in Figs. 1E and F is relatively large because the values are absoluteFig. 1. Force measurements. (A) Cardiomyocyte from the septum of one of the MyHC723-p
(B) Original force record of single MyHC723-myocyte. (C) Maximum active force per cro
MyHC723 cardiomyocytes (open bar) is 35% lower than for donor cells (hatched bar; *Pb0
pCa 4.5. Solid and dotted lines, ﬁts of a modiﬁed Hill equation yielding pCa50. (E) Absolut
(66 myocytes). (F) Absolute forces vs. pCa of M. soleus ﬁbers of healthy controls and of MyH
respective pCa50 values.force values of the individual muscle ﬁbers/myocytes which are quite
variable mostly due to uncertainties in determination of the cross-
sectional area of the cardiomyocytes/ﬁbers. When force–pCa relations
are normalized to forces at saturating calcium-concentration
(e.g., Fig. 1D), the variance is much smaller, and the shift in the
force–pCa-relationship by the MyHC723-mutation in M. soleus ﬁ-
bers is more obvious (cf. Fig. 5B in [12]).
3.2. Equally high expression level of mutant β-MyHC at mRNA and
protein level in both ventricular myocardium and M. soleus
The different effects of MyHC723 in cardiomyocytes and M. soleus
could be due to different levels of MyHC723 expression in the FHCmyo-
cardium compared to soleus ﬁbers. Using both a restriction digestatients mounted between motor for length control (left) and force transducer (right).
ss sectional area at saturating calcium-concentration (Fmax=Ftotal−Fpassive). Fmax of
.05). (D) Force at different calcium concentrations normalized to maximum force at
e forces vs. pCa of cardiomyocytes from donor (19 myocytes) and MyHC723-patients
C723-patient H27 (21 ﬁbers, respectively). Dotted vertical lines in (E) and (F) indicate
16 T. Kraft et al. / Journal of Molecular and Cellular Cardiology 57 (2013) 13–22analysis and real-time PCR as recently described [21], the relative abun-
dance ofmutated vs.wild-typeβ-MyHC-mRNAwas quantiﬁed. In cardi-
ac tissue with MyHC723 the fraction of mutated β-MyHC-mRNA was on
average 69% for patient H27 in different regions of the LV wall and 67%
for patientH29 (Supplementary Table 2). InM. soleus of patientH27 and
two other patients we previously found a fraction of 66±7% mutated
β-MyHC-mRNA. At the protein level, the fraction of mutated β-myosin
incorporated into the sarcomeres of soleus ﬁberswas 62±6% for patient
H27 and his brother [6]. Inmyocardium, preliminary protein quantiﬁca-
tion yielded very similar 63±11% ofmutated protein [21]. Thus, the ex-
tent of expression/incorporation of mutant myosin in the contractile
apparatus does not explain the discrepant functional effects between
M. soleus and myocardium.
3.3. Myocardium-speciﬁc reduction in phosphorylation of sarcomeric
proteins, which could account for functional differences compared to
M. soleus
To test for possiblemodiﬁers of contractile properties inmyocardium
[18,19,24], the phosphorylation status of sarcomeric proteins was deter-
mined. Proteins were separated by 1-dimensional gel electrophoresis
and stained with phospho-speciﬁc stain ProQ Diamond (Fig. 2A) and
protein stain SYPRO Ruby (Fig. 2B). Phosphorylation of cMyBP-C,
cTnI and myosin light chain 2 (MLC-2) was signiﬁcantly reduced
(Pb0.001) in MyHC723 compared to donor myocardium (Fig. 2C). On
average, cMyBP-C and MLC-2 phosphorylation were both reduced toFig. 2. Phosphorylation status of sarcomeric proteins. (A) ProQ Diamond and (B) SYPRO Rub
5, marker. (C) Data from donor samples (n=10 individuals) and samples of two and three
age, phosphorylation of cMyBP-C, cTnI and myosin light chain 2 (MLC-2) was signiﬁcantly
cantly lower compared to donor tissue only in LV tissue from patient H29.42% and cTnI phosphorylation to 11% in MyHC723 tissue compared to
donor tissue. Phosphorylation of cardiac troponin T (cTnT) was sig-
niﬁcantly reduced only in LV tissue from MyHC723 patient H29. The
substantial dephosphorylation of cTnI in MyHC723 myocardium was
conﬁrmed by Western immunoblot using an antibody speciﬁc for
non-phosphorylated cTnI-PKA sites (serines 23 and 24). The ratio
of dephosphorylated cTnI relative to Ponceau-stained actin in
MyHC723 myocardium was on average 1.66±0.3 (n=3 samples),
while in donor tissue no dephosphorylated cTnI was detected.
Isoform composition and phosphorylation status of ventricular
myosin light chains and cTnT in the myocardial samples were assessed
using 2D-PAGE [22]. In LV-myocardium of MyHC723 both MLC-2
isoforms (MLC-2 and MLC-2*) are dephosphorylated (Fig. 3B) com-
pared to donor tissue (Fig. 3A). However, only the decrease of the
phosphorylated MLC-2P and the increase of the unphosphorylated
MLC-2* were signiﬁcant (Table 1). The percentage of phosphorylated
MLC-1 did not differ between donor and MyHC723 myocardium. On
average, cTnT phosphorylation was reduced by 15% in MyHC723 tis-
sue compared to donor, while ProQ stained 1D-gels revealed a some-
what larger reduction in cTnT-P of 34%. This is only seen in tissue
from patient H29 (Fig. 2C), while for patient H27 cTnT phosphoryla-
tion was well preserved (Fig. 3B).
An additional difference betweenMyHC723 and donor ventricular tis-
suewas found for pro-apolipoprotein A-1 (GenBank number AAA51747.
1). Pro-apolipoprotein A-1 is a precursor of apolipoprotein A-1, which
is involved in lipid transport and metabolism and is a major protein ofy stained gels of LV tissue of donor (lane 1) and MyHC723-patient H27 (lanes 2–4). Lane
different areas of the LV-wall of MyHC723-patients H27 and H29, respectively. On aver-
reduced in MyHC723 compared to donor (Pb0.001). cTnT-phosphorylation was signiﬁ-
Table 1
Abundance of phosphorylated and unphosphorylated ventricular myosin light chains
(MLC) 1 and 2 and cardiac troponin T (cTnT) obtained from 2D-IEF-gels.
Donor MyHC723
cTnT-P 67.0±3.4 (4) 57.1±7.4 (4)
MLC-1P 13.2±2.7 (4) 12.6±1.7 (3)
MLC-2 36.4±4.5 (4) 52.2±6.4 (4)
MLC-2* 20.8±1.6 (4) 27.9±2.5 (4)a
MLC-2P 31.9±3.4 (4) 14.7±3.9 (4)b
MLC-2*P 11.0±2.2 (4) 5.1±2.9 (4)
Data±SEM, values in brackets indicate number of tissue samples (donor: n=4
individuals; MyHC723: 2 individuals (H27 and H29), samples from different LV areas
(n); cf. Supplementary Table 2). All values are given as percentage of total abundance of
17T. Kraft et al. / Journal of Molecular and Cellular Cardiology 57 (2013) 13–22plasmaHDL (high density lipoprotein). Gel-analysis of different parts of
the LV of H27 (Fig. 3B) revealed more than ﬁve times higher
pro-apolipoprotein in septum (pro-apo/actin ratio=34.6) compared
to tissue of two different regions of the free LV wall (pro-apo/actin
ratio=6.3±3) and to donor tissue (Pro-Apo/actin ratio=2.7).
To see whether MyHC isoform composition contributes to the dif-
ferent mutation effects in cardiomyocytes and slow M. soleus ﬁbers,
we analyzed the isoforms in the MyHC723 ventricular samples using
1D-gel electrophoresis. No signiﬁcant amounts of α-MyHC could be
detected in the samples of the patients (Supplementary Fig. S1).
Thus, it is unlikely that isoform composition is responsible for the ob-
served functional differences.the respective protein. MLC-2 and MLC-2*, unphosphorylated MLC-2 isoforms; MLC-2P
and MLC2*P, phosphorylated forms. aP=0.05 and bPb0.05, donor vs. MyHC723 (t-test).3.4. Reduced calcium-sensitivity inMyHC723myocytes after phosphorylation
with PKA
We next examined the inﬂuence of the signiﬁcantly reduced
(PKA-dependent) phosphorylation of cTnI and cMyBP-C in MyHC723
myocardium on calcium-sensitivity. As described above, the calcium-
sensitivity in MyHC723 cardiomyocytes did not differ from donor
myocytes. When we, however, repeated measurements of force–pCa
relations after PKA-treatment to match phosphorylation levels, the
resulting reduction in pCa50 was much larger in MyHC723 (ΔpCa50=
0.16±0.01, n=50 cells) than in donor cardiomyocytes (ΔpCa50=
0.04±0.01, n=9 cells; Pb0.001, Table 2). Thus, PKA treatment of
donor and MyHC723 cardiomyocytes uncovered a signiﬁcant difference
in the force–pCa relationships between MyHC723 (pCa50=5.40±
0.01) and donor (pCa50=5.51±0.02) cells once phosphorylation
was maximized for both tissues (Figs. 4A, B). The steepness of the
force–pCa relation (Hill coefﬁcient, nH) was very similar for donor
and MyHC723 cardiomyocytes and not signiﬁcantly affected by PKA-
treatment (Table 2). The reduced calcium-sensitivity in MyHC723-
cardiomyocytes upon PKA-treatment compared to donor is comparable
to the reduced calcium-sensitivity in M. soleus ﬁbers with MyHC723
(0.14 pCa units) [12].Fig. 3. 2D-gels illustrating MLC composition of donor LV tissue (A) and septum of fail-
ing MyHC723 myocardium (patient H27; B). IEF, isoelectric focusing; TnT and TnT-P,
unphosphorylated and monophosphorylated cardiac troponin T; MLC-1, ventricular
myosin light chain 1; MLC-2 and MLC-2*, two isoforms of ventricular myosin light
chain 2, both partly phosphorylated (MLC-2P and MLC-2*P, respectively). In septum
of MyHC723-patient H27 a quite prominent spot is seen, identiﬁed by mass spectrom-
etry as pro-apolipoprotein A-1 (Pro-ApoA-1).To ﬁnd out whether the reduced calcium-sensitivity is due to
changes in cross-bridge cycling kinetics we recorded the rate constant
of force redevelopment (ktr) after PKA-treatment. Fig. 4E shows that
ktr at different calcium-concentrations is essentially the same for
donor and MyHC723 myocytes. For M. soleus ﬁbers of controls and
MyHC723 also no difference in the ktr–pCa relationship was found
(data not shown). Nevertheless, the mutation could still cause changes
in parameters of cross-bridge cycling kinetics (fapp and gapp) which
do not signiﬁcantly affect the overall rate constant ktr (see discussion
for details).
To test whether the reduced MLC-2 phosphorylation in MyHC723
cardiomyocytes might also affect their calcium-sensitivity, we incu-
bated MyHC723 and donor cardiomyocytes with protein phosphatase
PP-1 [24] and subsequently measured force–pCa relations before
and after additional PKA-treatment. PP-1 adjusts all myocytes to a
similarly low phosphorylation level particularly of MLC-2 [22,24]. No
signiﬁcant difference of pCa50 was observed after treatment with PP-1
(Fig. 4F). Subsequent PKA incubation reduced pCa50 to a similar extent
as seen without PP-1-pretreatment (Fig. 4A). Phospho-gel analysis of
tissue samples after PP-1 and subsequent PKA treatment on average
showed similar phosphorylation levels of cMyBP-C, cTnI and MLC-2
for donor and MyHC723 hearts (Supplementary Fig. S2). This indicates
that the signiﬁcant reduction of pCa50 seen in MyHC723 myocytes
compared to donor after PP-1–PKA treatment (Fig. 4F) most likely
is not due to different phosphorylation levels of these proteins in donor
and MyHC723 cardiomyocytes. In studies on M. soleus ﬁbers, which
also showed reduced pCa50 with MyHC723, all ﬁbers were pre-treated
with PP-1 to exclude effects of different phosphorylation of slow
MLC-2 (for details see [12]).3.5. Lower active and passive forces related to structural deﬁciencies
The lower Fmax of MyHC723 myocytes compared to donor myocytes
was not restored by phosphorylation of PKA sites and dephosphoryla-
tion of PP-1 sites (Fig. 4D). As a possible reason for the reduction in
Fmax, we looked at changes in morphology of the ventricular tissue at
the cellular and subcellular level. Light microscopy (Fig. 5A) of myocar-
dial tissue of bothMyHC723 patients demonstrated extensive areaswith
intercellular connective tissue, which was similar in the LV wall of both
patients. In the septum of patient H27, it was even more pronounced.
This was not seen in donor myocardium. Probably most relevant for
the reduced force generation of individual cardiomyocytes are massive
changes in sarcomeric ultrastructure of MyHC723 compared to donor
cardiomyocytes. Electron microscopy revealed not only Z-disc irregu-
larities but also pronounced disarray (Fig. 5B) and reduction in density
of myoﬁbrils by 26% in MyHC723 cardiomyocytes compared to donor
(Fig. 5C). Importantly, in MyHC723 cardiomyocytes the observed disar-
ray, i.e., the deviation of the myoﬁbril orientation from a common axis
(double arrows in Fig. 5B, bottom panel) indicates a deviation from a
common force vector.
Fig. 4. Effects of PKA-incubation. (A) The calcium-sensitivity (pCa50) is signiﬁcantly more reduced in MyHC723 cells compared to donor cells (Pb0.001 for ΔpCa50). (B) Force–pCa
relations of donor (triangles) and MyHC723 cardiomyocytes (circles) before PKA (black open symbols) and after PKA (gray ﬁlled symbols) illustrate shift of the MyHC723 force–pCa
curve to lower calcium-sensitivity after PKA treatment. Modiﬁed Hill equation ﬁtted to data points. (C) In untreated cardiomyocytes Fpassive in MyHC723 cardiomyocytes is signif-
icantly smaller than in donor. In MyHC723 PKA incubation reduced Fpassive signiﬁcantly (Pb0.05). (D) Fmax in donor and failing MyHC723 cardiomyocytes is unaffected by PKA incu-
bation. (E) Rate constant of force redevelopment (ktr) at different calcium-concentrations was essentially the same for donor (triangles) and MyHC723 cardiomyocytes (circles).
(F) After PP-1-pretreatment, PKA incubation reduced pCa50 of MyHC723 myocytes signiﬁcantly (#Pb0.01) but non-signiﬁcantly in donor cells. ⁎Pb0.05, MyHC723 vs. donor; #Pb0.05,
before vs. after PKA in A, C and E.
Table 2
Calcium-sensitivity (pCa50), Hill coefﬁcient (nH) of force–pCa-relations, active (Fmax) and passive force (Fpassive), and rate constant of force redevelopment (ktr) at pCa 4.5 of donor
vs. MyHC723 myocytes before and after treatment with PKA.
pCa50 nH Fmax
(kN/m2)
Fpassive
(kN/m2)
ktr
(1/s)
Donor 5.56±0.01
(19)
3.31±0.21
(19)
34.7±3.8
(19)
4.49±0.59
(19)
0.85±0.05
(19)
MyHC723
(H27 & H29)
5.56±0.01
(66)
3.03±0.08
(66)
23.8±1.7b
(67)
3.24±0.27b
(67)
0.79±0.03
(64)
After PKA
Donor 5.51±0.02a
(9)
3.46±0.23
(8)
33.3±6.5
(8)
4.17±0.88
(8)
0.80±0.07
(8)
MyHC723
(H27 & H29)
5.40±0.01a,b
(50)
3.22±0.09
(50)
24.2±1.8
(51)
2.36±0.23a,b
(51)
0.81±0.03
(45)
Data±SEM, number in brackets indicates myocytes measured. Donor includes 5 and 4 individuals before and after PKA, respectively. MyHC723 includes two individuals; from pa-
tient H27 myocytes from 4 muscle pieces of different LV regions were measured (cf. Supplementary Table 2).
a Pb0.05, before vs. after PKA (one-way ANOVA).
b Pb0.05, donor vs. MyHC723 (t-test).
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19T. Kraft et al. / Journal of Molecular and Cellular Cardiology 57 (2013) 13–22In addition, changes in cross-bridge turnover kinetics could contrib-
ute to reduced Fmax in MyHC723 even though the rate constant of force
redevelopment (ktr) at saturating calcium concentrations, ktrmax, wasFig. 5. Light- and electron-microscopy of myocardial tissue and myocyte ultrastructure. (A) D
areas with interstitial connective tissue (dark red in Elastica van Gieson-stained sections; m
ordered myoﬁbrils and sarcomeres, while in both patients (H27 and H29) Z-discs are irregula
ﬁbrillar density is reduced (magniﬁcation: 4400×). (C) Substantially reduced myoﬁbrillar dvery similar in MyHC723 and donor cardiomyocytes and remained
unchanged by PKA-treatment in both groups (Table 2; Fig. 4E). Changes
in cross-bridge kinetics, which do not affect ktr could still contributeifferent from donor myocardium, LV myocardium of patients H27 and H29 shows large
agniﬁcation: 100×). (B) At the subcellular level, LV myocardium from donor has well
r, myoﬁbrillar axes are highly variable (disarray, indicated by double arrows) and myo-
ensity in myocytes of both patients (#Pb0.01, *Pb0.001).
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(see Discussion for more details).
Besides reduced Fmax, also Fpassive was lower in MyHC723
cardiomyocytes compared to donor. The difference was 1.25 kN/m2
(Fig. 4C; Table 2) and increased upon PKA incubation to 1.81 kN/m2,
mainly due to a decrease in Fpassive for the MyHC723 cardiomyocytes.
Force at maximum calcium activation (pCa 4.5) was essentially unaf-
fected by PKA-treatment both in MyHC723 and donor, i.e. the difference
in Fmax remained unchanged (Fig. 4D; Table 2).
4. Discussion
Changes in contractile function of myocardium triggered by FHC-
mutations can be direct effects of such mutations on sarcomeric func-
tions, effects of additional changes like modiﬁed protein phosphoryla-
tion, or the result of morphological alterations. In the present study,
we attempted to discern contributions of these different factors on
contractile function of cardiomyocytes with myosin mutation R723G.
We (i) analyzed contractile function ofMyHC723-cardiomyocytes before
and after matching protein phosphorylation of donor and MyHC723-
cardiomyocytes and (ii) analyzedmyoﬁbrillar density and organization
via EM. Finally, we compared data of MyHC723-cardiomyocytes and
previous data fromM. soleus ﬁbers with the same mutation [12].
4.1. Reduced calcium-sensitivity becomes detectable by PKA-treatment
Unexpectedly, the MyHC723 cardiomyocytes isolated from tissue
samples of affected patients showed the same calcium-sensitivity as
donor myocytes. Phosphorylation of cTnI, however, was much lower
in both patients' hearts compared to donor myocardium, which is
expected to shift the force–pCa relation to higher calcium-sensitivity
[19]. Matching phosphorylation levels of donor- and MyHC723-
cardiomyocytes by phosphorylation of PKA-dependent sites and de-
phosphorylation of PP-1 sites resulted in reduced calcium-sensitivity
of MyHC723-cardiomyocytes, which was comparable to the reduced
calcium-sensitivity found earlier in M. soleus ﬁbers with the same
R723G mutation [12]. Such lower calcium-sensitivity is at odds with
the idea that FHC-mutations are associated with increased calcium-
sensitivity, while in DCM reduced calcium-sensitivity predominates
[25,26]. The reason for reduced cTnI-phosphorylation in MyHC723-
cardiomyocytes is not clear. It could be due to the end-stage HF of the
patients since earlier studies on idiopathic dilated and ischemic failing
myocardium without sarcomeric mutations showed similarly reduced
cTnI-phosphorylation [15,18,19]. The reduced cTnI-phosphorylation,
however, might also reﬂect a hypertrophic cardiomyopathy-typical
posttranslational modiﬁcation as it was also observed in non-failing
myectomy-tissue from patients with hypertrophic obstructive cardio-
myopathy [9,27].
The reduction in calcium-sensitivity when phosphorylation levels
are matched is most likely caused by changes in cross-bridge cycling
kinetics. It has been shown that calcium-sensitivity depends on the
ratio of the rate constants of cross-bridge cycling, fapp/gapp. This
ratio can modulate contractile function independent of the regula-
tory protein complex on actin [28]. Isometric force (F) is determined
by F=n·F*·fapp/(fapp+gapp) [28], i.e. by the transition of the cross-
bridges into force-generating states (fapp) and their return to non-
force-generating states (gapp), by F*, the mean force generated by each
myosin head, and by n, the total number of actively cycling myosin
heads which can bind to actin within a half sarcomere (depending e.g.,
on ﬁlament overlap). Possible changes in F* (as found for MyHC723 my-
osin heads [13]) and n are expected to affect force generation at each
calcium-concentration similarly, therefore changes in these parameters
cancel out in normalized force–pCa relationships. It has been shown
that an increase in gapp and/or a decrease in fapp, i.e., any decrease in
fapp/gapp causes reduced force generation with a shift in the force–pCa
relationship to the right, i.e., reduced calcium-sensitivity [28].Measurements of ktr (ktr=fapp+gapp; [28]) revealed essentially no
difference for controls and MyHC723-cardiomyocytes at all calcium-
concentrations. This, however, does not preclude reciprocal changes in
the two rate constants that reduce fapp/gapp but leave fapp+gapp essen-
tially unchanged. Such reciprocal changes could cause a suppression of
maximum force and a decrease in calcium-sensitivity. We calculated
possible changes of fapp and gapp based on the measured values for ktr
and for Fmax at full and half-maximal activation. As value for gapp we
took 0.17 s−1 from data on heart myoﬁbrils at 15 °C (c.f. [10]; slow
kREL corresponds to gapp). The reduced normalized force of MyHC723
cardiomyocytes seen after PKA treatment at half-maximal activation
(Fig. 4B) can be accounted for within experimental error by a ~28% in-
crease in gapp and a ~40% decrease in fapp compared to donor myocytes.
The increased unloaded shortening velocity observed in the M. soleus
ﬁbers also suggests a faster gapp for the MyHC723 myosin.
In summary, reduced calcium-sensitivity is most likely the result
of changes in cycling kinetics of theMyHC723myosin caused by themu-
tation. Fmax is also affected by the force contribution of the individual
molecule (F*) which is enhanced for this mutation due to increased re-
sistance to elastic distortion [13]. Thus, increased force contribution per
myosinmolecule and reduced calcium-sensitivity are not contradictory.
4.2. Reduced maximum active and passive forces
The reduced Fmax in MyHC723 cardiomyocytes by 31% is in strong
contrast to 20% increase in Fmax of soleus ﬁbers with this mutation
[13]. For patient H27 the skeletal biopsy was taken only one year be-
fore the heart transplant, this short time difference is unlikely to be
responsible for such drastic force reduction. Reduced Fmax is in con-
trast to most ﬁndings in non-FHC-related heart failure where Fmax is
often unchanged [29]. However, in cardiomyocytes isolated from
myectomy tissue of hypertrophic cardiomyopathy patients with LV
outﬂow tract obstruction Fmax was also reduced [9,27]. Similar expres-
sion levels of mutated β-MyHC-mRNA and protein in myocardium
and soleus [21] showed that the discrepancy is not due to altered ex-
pression of mutated myosin. In addition, studies using X-ray diffraction
and confocal microscopy indicated that myosin-converter-domain mu-
tations like R723G, R719W or G741R, do not alter sarcomeric composi-
tion and ordered assembly of myoﬁlaments in triton-permeabilized
M. soleus ﬁbers ([30], own unpublished observations). In general, as-
sembly and formation of the thick ﬁlaments are normal with other
myosin head-domain mutations [31].
Most likely, a substantial part of the reduced Fmax in MyHC723
cardiomyocytes is due to the signiﬁcantly lower density and the dis-
array of myoﬁbrils observed by electron microscopy. We estimated
Fmax of the MyHC723 myocytes expected if myoﬁbrillar density were
not lowered by 26%. In this case, Fmax would be increased from
24.2 kN/m2 (Table 2) to 32.8 kN/m2, which is essentially the same as
Fmax of the donor myocytes. Besides lowermyoﬁbrillar density electron
microscopy also showed that myoﬁbrils in MyHC723 cardiomyocytes
deviate from the major force axis. Such myoﬁbrils will only partly
contribute to maximum force generation in axial direction, as has
been shown for similarly compromisedmicroarchitecture in dystrophic
muscle cells [32]. Thus, reduced Fmax caused by disarray and reduced
number of myoﬁbrils very likely outweighs the increased force per my-
osin head caused by the mutation, as seen in M. soleus ﬁbers with
MyHC723 [13]. M. soleus ﬁbers of controls and MyHC723 patients both
have a highly ordered sarcomeric structure and show no indication
of reduced myoﬁbrillar density.
Phosphorylation of PKA sites and dephosphorylation of PP-1 sites did
not restore Fmax of MyHC723 myocytes. Thus, PKA- and PP-1-dependent
signaling does not contribute to the reduced Fmax. This is supported by
previous work on failing myocardium with similarly low MLC-2 phos-
phorylation showing unaltered Fmax of cardiomyocytes [19]. However,
it cannot be completely excluded that different MLC-isoform expression
in soleus andmyocardiummay contribute to different effects ofmutation
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present and a different essential light chain (MLC-1slow-a) can be
expressed [4]. Yet, theMLC-1 is in very close proximity to the converter
region of the myosin head domain where the mutation is located.
Therefore, changes in possible interactions between myosin heavy
chain and MLC-1 could inﬂuence the effect of MyHC723 on stiffness
and force of the individual mutated myosin heads [13] and thus affect
Fmax differently inM. soleus and cardiomyocytes.
Fpassive of myocytesmainly depends on the elastic properties of titin,
which spans each half sarcomere from the Z-disc to theM-line, anchor-
ing themyosinﬁlaments. Therefore, the loss and distortion ofmyoﬁbrils
may also explain the 28% lower Fpassive ofMyHC723 cardiomyocytes. This
is actually different from heart failure [24] and from cardiomyocytes
isolated frommyectomy tissue of patients with hypertrophic cardiomy-
opathy [9,27] where Fpassive was unchanged. The additional reduction of
Fpassive by rephosphorylation with PKA could well be a direct conse-
quence of titin phosphorylation [33], indicating dephosphorylated
titin in the failing FHC myocardium. For the patient's myocardial func-
tion and particularly for impaired diastolic ﬁlling, however, themassive
interstitial ﬁbrosis of the left ventricular wall and of the septum seen
in histology is probably the major disadvantage, despite the reduced
Fpassive of the isolated cardiomyocytes.
4.3. The course of FHC development
With a study on cardiac samples from FHC patients at end-stage
heart failure it is essentially not possible to assess initial effects and
early stages of the development of FHC phenotype features. However,
based on functional studies on M. soleus ﬁbers with the same muta-
tion [12,13] and on analysis of expression levels of mutated myosin
in myocardium and M. soleus of the heterozygous patients [21], we
may develop the following hypothesis: We assume that the mutation
effects observed inM. soleus ﬁbers, where no myoﬁbrillar deﬁciencies
and phosphorylation changes were obvious, reﬂect the situation in
cardiomyocytes of the patients at the very beginning of the disease.
In this case, in MyHC723 cardiomyocytes at early stages of disease only
a slight change of average force generation at submaximal calcium-
concentrations would be detectable (Fig. 1F) and major adaptations
and myoﬁbrillar deﬁciencies may still be absent.
We hypothesize that subsequently disarray develops in myocardi-
um because of variable expression of mutated and wild-type myosin
in individual myocytes, resulting in functional variability among indi-
vidual cells [12,21]. This is based on studies on MyHC723 muscle ﬁbers
where we found, different from control ﬁbers, large variability in
calcium-sensitivity and force generation among individual MyHC723-
ﬁbers ranging from near normal values to highly signiﬁcant deviations
from control [12]. If in myocardium similar variability exists among
neighboring cardiomyocytes at early stages of the disease, imbalances
in force generation among cardiomyocytes and myoﬁbrils will trigger
non-uniform contraction of myocardial tissue, i.e., overcontraction vs.
overstretching of individual myocytes. Due to the arrangement of
cardiomyocytes in a network with cells in series and branched cells,
in the long run non-uniform contraction results in cellular andmyoﬁbril-
lar disarray. InM. soleus, due to the unbranched, parallel arrangement of
ﬁbers, no such disarray is expected to develop. In myocardium, disarray
with structural damage or even loss of myocytes under increased strain
will cause impaired force output, presumably triggering hypertrophy
for compensation. Alterations of contractile function of cardiomyocytes
such as reduced cTnI-phosphorylation always affect both mutated
and wild-type acto-myosin-complexes in the same way, and there-
fore cannot compensate for the imbalances in force generation. To
test unequal MyHC723 expression which is the basis of this hypothesis
requires downscaling of β-MyHC-mRNA quantiﬁcation to the level of
individual cardiomyocytes.
In conclusion, the observed functional differences betweenM. soleus
ﬁbers and cardiomyocytes with mutation MyHC723 can be explainedby alterations of protein phosphorylation and morphology of MyHC723-
cardiomyocytes. These alterations could be due to HF in these patients
but might also reﬂect FHC-phenotype-related posttranslational modiﬁ-
cations, as these were observed in myectomy-tissue from patients with
hypertrophic obstructive cardiomyopathy without HF [9,27]. Thus, in
the case of MyHC-mutations in FHC, M. soleus biopsies appear useful
for functional studies trying to identify direct effects of FHC-mutations
and to suggest strategies for early prevention of FHC-typical features
in young mutation carriers. Yet, long-term studies on contractility
and ultrastructure of the myocardium of genotyped family members
beginning at very young age and studies on animal models with near
human physiology are needed to more completely understand human
FHC-pathogenesis.
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